Backgrounds/Aims Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood.
Methods The Tm6sf2167K knock-in (KI) mice were subjected to high-fat diet (HFD). Hepatic lipid levels of Tm6sf2167K KI mice were detected by lipidomics analysis. Thin-layer chromatography (TLC) was used to measure the newly synthesized triglyceride (TG) and phosphatidylcholine (PC).
Results The TM6SF2 E167K variant significantly aggravated hepatic steatosis and injury in HFD-induced mice. Decreased polyunsaturated PC level and increased polyunsaturated TG level were found in liver tissue of HFD-induced Tm6sf2167K KI mice. Mechanistic studies demonstrated that the TM6SF2 E167K variant increased the interaction between TM6SF2 and PNPLA3, and impaired PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC. The TM6SF2 E167K variant increased the level of fatty acid-induced malondialdehyde and reactive oxygen species, and decreased fatty acid-downregulated cell membrane fluidity. Additionally, the TM6SF2 E167K variant decreased the level of hepatic PC containing C18:3, and dietary supplementation of PC containing C18:3 significantly attenuated the TM6SF2 E167K-induced hepatic steatosis and injury in HFD-fed mice.
Conclusions The TM6SF2 E167K variant could promote its interaction with PNPLA3 and inhibit PNPLA3-mediated transfer of PUFAs from TG to PC, resulting in the hepatic steatosis and injury during MASLD progression. PC containing C18:3 could act as a potential therapeutic supplement for MASLD patients carrying the TM6SF2 E167K variant.
Citations
Citations to this article as recorded by
Association of Circadian Rhythms With the Risk of Chronic Liver Disease: Findings From a Large Prospective Study Rong Yang, Can Shen, Yu Jia, Yi Yao, Yiheng Zhou, Yu Cheng, Yonglang Cheng, Rui Zeng, Zhi Wan, Qian Zhao, Dongze Li, Xiaoyang Liao Clinical and Translational Gastroenterology.2026; 17(1): e00949. CrossRef
High-protein diets and metabolic dysfunction-associated steatotic liver disease: A double-edged sword in liver health Hong-Yuan Yin, Qian-Hui You, Wei-Jie Zhang, Guang Ji, Yan-Qi Dang World Journal of Gastroenterology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models Jack Leslie, Kishore A. Krishnamurthy, Indresh K. Gopalsamy, Patricia Inacio, Meritxell Huch, Suchira Gallage, Fiona Oakley, Michele Vacca Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 286. CrossRef
1-O-acetylbritannilactone alleviates high-fat diet-induced fatty liver by covalently targeting NLRP3 Tianyang Jin, Yanni Zhao, Tingxin Xu, Yi Fang, Yaqian Cui, Wenqi Liu, Yongqiang Xiong, Jiaxi Ye, Wu Luo, Bo Hong, Guang Liang, Xiang Hu, Lijiang Huang, Yi Wang International Immunopharmacology.2026; 174: 116351. CrossRef
Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang BMJ Open Gastroenterology.2026; 13(1): e002123. CrossRef
Lipid metabolism-MAFLD crosstalk: mechanisms and therapy Bojia Li, Shengai Piao, Yin Fu, Qiang Fu, Peiyao Qin, Weitai Kong, Yidi Ma, Zhe Zhang, Xue Fang, Xiaoyang Hu Frontiers in Endocrinology.2026;[Epub] CrossRef
Current status survey and risk factor analysis of metabolic dysfunction-associated steatotic liver disease among adolescents in Hainan Province Shuo Zhou, Daya Zhang, Runyu Chen, Yan-ting Lv, Da Li, Xianfeng Huang, Fengjiao Mao, Shimei Huang, Shiju Chen, Chen Chen, Ying Mo, Yiping Du, Yuliang Huang, Fan Zeng, Qicen Yao, Feihu Bai Scientific Reports.2026;[Epub] CrossRef
Selenium Protects Against Cadmium-Induced Hepatotoxicity via Regulation of Lipid Metabolism and Inflammatory Pathways Zilong Wu, Xinyi Chen, Xiaoying Pan, Kai Luo, Zixiong Zhang, Changyu Zhou, Haibo Wang, Chuying Huang Frontiers in Bioscience-Landmark.2026;[Epub] CrossRef
Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review Aleksandra Klisic, Ratko Tomašević, Slavko Djuraskovic, Filiz Mercantepe, Ana Ninic Archives of Medical Science.2026;[Epub] CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Microbial metabolites contribute to the pathogenesis of metabolic dysfunction-associated fatty liver disease in high-fat diet-fed mice Kai-Wen Cai, Zhen-Chuan Lin, Xue-Mei Zhang, Jia-Yun Yu, Tian-jiao Cui, Yi-Qing Zhang, Rong-Hua Zou, Zhi-Hua Zheng, Yao-Liang Zhou, Ting Zhu, Yong-Ping Lu Microbial Pathogenesis.2026; 218: 108634. CrossRef
Genetics and epigenetics in tumor necrosis factor-alpha (TNF-α) and transmembrane 6 superfamily member 2 (TM6SF2) in alcohol induced liver cirrhosis Bhagyalakshmi Shankarappa, Jayant Mahadevan, Pratima Murthy, Biju Viswanath, Harshad Devarbhavi, Sanjeev Jain, Meera Purushottam Frontiers in Medicine.2026;[Epub] CrossRef
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Baokai Sun, Likun Zhuang Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Andrea Caddeo, Rosellina M. Mancina Clinical and Molecular Hepatology.2025; 31(1): 293. CrossRef
Causal roles of immune cells and metabolites in chronic pancreatitis: a mendelian randomization study Chao Zhang, Tao Yang, Yuan Yu, Qian Jia, Wan-Meng Xiao, Sha Liu, Ze-Hui Yu, Cheng-Li Wen, Yan Wei, Hao Li, Mu-Han Lü Hereditas.2025;[Epub] CrossRef
Effects of polyphenols on non-alcoholic fatty liver disease: a case study of resveratrol Ying Zhao, Jiali Ren, Weisan Chen, Xinchen Gao, Hongjian Yu, Xiankuan Li, Yanchao Zheng, Jinlong Yang Food & Function.2025; 16(8): 2926. CrossRef
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina American Journal of Physiology-Cell Physiology.2025; 328(5): C1637. CrossRef
Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement Indrajit Bhattacharya, Deep Kumar Maity, Amit Kumar, Sampriti Sarkar, Teeshyo Bhattacharya, Amrita Sahu, Remya Sreedhar, Somasundaram Arumugam Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(10): 13647. CrossRef
Liver disease trends in the Asia-Pacific region for the next 50 years Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(3): 671. CrossRef
First
Prev
